Fig. 4.
Fig. 4. Heterogeneous IL-6 production by myeloma cells. / Double-fluorescence staining of BMMC from 4 representative patients with MM for syndecan-1 and cytoplasmic IL-6 expression showed variable IL-6 production by myeloma cells. I indicates syndecan-1−/IL-6+ BMMC; II, syndecan-1+/IL-6+ BMMC; and III, syndecan-1+/IL-6− BMMC. The proportion of IL-6–producing cells among syndecan-1+ cells was evaluated as follows: (percentage of syndecan-1+/IL-6+BMMC divided by percentage syndecan-1+/IL-6−BMMC) times 100. The patient with resistant relapse (A) showed the largest proportion (99%) compared with patients with a recent diagnosis (B, 65%; and C, 22%) and patients in remission (D, 26%).

Heterogeneous IL-6 production by myeloma cells.

Double-fluorescence staining of BMMC from 4 representative patients with MM for syndecan-1 and cytoplasmic IL-6 expression showed variable IL-6 production by myeloma cells. I indicates syndecan-1−/IL-6+ BMMC; II, syndecan-1+/IL-6+ BMMC; and III, syndecan-1+/IL-6− BMMC. The proportion of IL-6–producing cells among syndecan-1+ cells was evaluated as follows: (percentage of syndecan-1+/IL-6+BMMC divided by percentage syndecan-1+/IL-6−BMMC) times 100. The patient with resistant relapse (A) showed the largest proportion (99%) compared with patients with a recent diagnosis (B, 65%; and C, 22%) and patients in remission (D, 26%).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal